COVID-19: Lung-Centric Immunothrombosis

Frontiers in Cellular and Infection Microbiology

Peter R. Kvietys¹  Sana Kadan¹  Ahmed Yaqinuddin¹  Hana. M. A. Fakhoury¹  Khaled Al-Kattan¹  Eid Al-Mutairy² 

[1] College of Medicine, Alfaisal University, Riyadh, Saudi Arabia;Department of Medicine, King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh, Saudi Arabia;

关键词: acute respiratory distress syndrome (ARDS);    coronavirus;    COVID-19;    cytokine storm;    NET;    SARS-CoV-2;   

DOI  :  10.3389/fcimb.2021.679878

来源: Frontiers

【 摘 要 】

The respiratory tract is the major site of infection by SARS-CoV-2, the virus causing COVID-19. The pulmonary infection can lead to acute respiratory distress syndrome (ARDS) and ultimately, death. An excessive innate immune response plays a major role in the development of ARDS in COVID-19 patients. In this scenario, activation of lung epithelia and resident macrophages by the virus results in local cytokine production and recruitment of neutrophils. Activated neutrophils extrude a web of DNA-based cytoplasmic material containing antimicrobials referred to as neutrophil extracellular traps (NETs). While NETs are a defensive strategy against invading microbes, they can also serve as a nidus for accumulation of activated platelets and coagulation factors, forming thrombi. This immunothrombosis can result in occlusion of blood vessels leading to ischemic damage. Herein we address evidence in favor of a lung-centric immunothrombosis and suggest a lung-centric therapeutic approach to the ARDS of COVID-19.

【 授权许可】

CC BY